New York, United States, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The demand for continuous blood glucose monitors (CGM) is rising. People with diabetes are among the most vulnerable to severe complications caused by COVID-19. During the COVID-19 pandemic, there has been more preference for the use of virtual clinics and telemedicine to monitor diabetics. For example, the UK's National Health Service revised its clinical guidance to promote remote contacts through mobile, email, and video conferencing. This has contributed to increased demand for apps for diabetic treatment, which can exchange data remotely.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/continuous-blood-glucose-monitoring-market/request-sample
Market Overview
With CGM tools, there are considerably more data available, which can help patients and healthcare providers enhance glycemic control and eventually increase patients' self-management. CGM's increasing demand is driven mainly by growing product awareness and rapid responses from companies to the COVID-19 pandemic. Both Dexcom and Abbott have been given FDA clearance to make available CGM systems for use in hospital settings and other health care facilities. Health Canada recently announced the Dexcom G6 CGM program's provisional authorization for expanded use of Canadian hospitals.
Remote monitoring of patients with diabetes with CGM devices will help minimize healthcare providers' exposure and conserve personal protective equipment. Along with the insulin giants Novo Nordisk and Eli Lilly, CGM firms have launched new patient aid services to help existing CGM patients who have lost insurance due to the US COVID-19 pandemic. Dexcom has reduced its CGM costs for its current, eligible patients to USD 45 per 90-day supply. The pandemic has increased demand for the establishment of electronic blood glucose records for diabetes patients. COVID-19 has opened up new possibilities for CGM systems to gain popularity in the diabetic care brand.
Report Scope
| Report Metric | Details |
| Market Size | USD 14.92 Billion by 2030 |
| CAGR | 12.3% (2022-2030) |
| Historical Data | 2019-2020 |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, End-User, Region |
| Geographies Covered | North America, Europe, Asia-Pacific, LAME and Rest of the World |
| Key Companies Profiled/Vendors | Abbott, Dexom Inc., Roche Diagnostics, Bayer AG, Medtronic Plc., Novo Nordisk, Ypsomed AG, Senseonics Incorporated, Insulet Corporation. |
| Key Market Opportunities | Rapid Growth In Medical Devices Industry Enhances Continuous Blood Glucose Monitoring Market |
| Key Market Drivers | Increase in Diabetes Incidence and to Reduce the Complications Associated with the Disease |
Buy Now Full Report @ https://straitsresearch.com/buy-now/continuous-blood-glucose-monitoring-market
Regional Analysis
The regions of North America, Europe, Asia-Pacific, South America, the Middle East, and Africa are majorly considered in the analysis of the global continuous blood glucose monitoring market.
Diabetes is prevalent in a significant number of North American nations. The United States commanded the highest proportion of the global market for glucose monitoring because of the vast number of patients and widespread adoption of cutting-edge technologies. The burden of high diabetes spending is felt by the nations in the Middle East and Africa. In the MENA region, diabetes affects one in every eleven people, according to IDF.
In the Middle East and North Africa, ALRT Diabetic Solution provides a user-friendly and accessible contact network between the patient and the diabetes healthcare team.
Market Highlights
- The global continuous blood glucose monitoring market size was valued at USD 5.25 billion in 2021. It is projected to reach USD 14.92 billion by 2030, growing at a CAGR of 12.3% during the forecast period (2022-2030).
- Based on the product types, sensors accounted for the largest revenue share in terms of the market revenue. Repeat purchase of the sensors instead of other components like receivers and transmitters is one of the key factors for the largest market share. However, combined insulin pumps with continuous blood glucose monitoring represent lucrative market opportunities.
- Based on the end-user, the home care segment is expected to grow with the fastest CAGR. Increasing adoption of continuous blood glucose monitoring in homecare is driving the adoption in the homecare segment.
- Regionally, in terms of revenue, North America is the largest contributor in terms of market size.
Competitive Players in the Global Continuous Blood Glucose Monitoring Market
- Abbott
- Dexom Inc.
- Roche Diagnostics
- Bayer AG
- Medtronic Plc.
- Novo Nordisk
- Ypsomed AG
- Senseonics Incorporated
- Insulet Corporation
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/continuous-blood-glucose-monitoring-market/request-sample
Market Segmentation
By Product
- Transmitter
- Receiver
- Sensor
- Insulin Pump
By End-User
- Hospitals and Clinics
- Homecare
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Central and South America and the Caribbean
- The Middle East and Africa
TABLE OF CONTENT
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Global Continuous Blood Glucose Monitoring Market insights
3.1 Industry Impact Forces
3.2 Drivers
3.2.1 Rising Diabetes Prevalence
3.2.2 Higher convenience and significant advantages offered by the CGM devices
3.3 Restraints
3.3.1 High cost and low availablity of CGM systems in the developing countries
3.3.2 Insufficient reimbursement
3.4 Opportunities
3.4.1 COVID-19 opens new opportunities for CGM systems
3.4.2 Extensive End-User range of CGM devices
3.5 Challenges
3.5.1 Low penetration of developing countries
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Threat of Substitutes
3.6.4 Threat of New Entrants
3.6.5 Competitive Rivalry
3.7 Value Chain Analysis
3.8 Impact of COVID-19 on the market
3.9 Cost Structure Analysis
3.9.1 Manufacturing Cost Structure Analysis
3.10 Sales Channel Analysis
3.10.1 Product 1
3.10.2 Product 2
3.10.3 Product 3
3.11 Technology Encroachments focus on refining patient convenience and becoming integrated devices
3.11.1 Finger Pricks
3.11.2 Semi-Invasive Monitors
3.11.3 Implants
3.11.4 Non-Invasive Monitors
3.11.5 Groundbreaking Smart, Connected Monitors to Foster Care Delivery Support
4 Product Overview
4.1 Introduction
4.1.1 Market Size and forecast (Value)
4.1.2 Market Size and forecast (Volume)
4.2 Transmitter
4.2.1 Market Size &forecast (Value)
4.3.1 Market Size &forecast (Volume)
4.4 Sensor
4.4.1 Market Size &forecast (Value)
4.4.2 Market Size & forecast (Volume)
4.5 Insulin Pumps
4.5.1 Market Size &forecast (Value)
4.4.2 Market Size & forecast (Volume)
5 End-User Overview
5.1 Introduction
5.1.1 Market Size and forecast (Value)
5.1.2 Market Size and forecast (Volume)
5.2 Hospitals and clinics
5.2.1 Market Size & forecast (Value)
5.2.2 Market Size & forecast (Volume)
5.4 Home Care
5.4.1 Market Size & forecast (Value)
5.4.2 Market Size & forecast (Volume)
5.5 Other End-Users
5.5.1 Market Size & forecast (Value)
5.5.2 Market Size & forecast (Volume)
6 Regional Overview
6.1 Introduction
6.1.1 Market Size &forecast (Value)
6.2 America
6.2.1 North America
6.2.1.1 The U.S.
6.2.1.1.1 By Product
6.2.1.1.2 By End-User
6.2.1.2 Canada
6.2.1.2.1 By Product
6.2.1.2.2 By End-User
6.2.1.3 Mexico
6.2.1.3.1 By Product
6.2.1.3.2 By End-User
6.2.2 Central and South America and the Caribbean
6.2.2.1 By Product
6.2.2.2 By End-User
6.2.2.2.1 Brazil
6.2.2.2.1.1 By Product
6.2.2.2.1.2 By End-User
6.2.2.2.2 Argentina
6.2.2.2.2.1 By Product
6.2.2.2.2.2 By End-User
6.2.2.2.3 Rest ofCentral and South America and the Caribbean
6.2.2.2.3.1 By Product
6.2.2.2.3.2 By End-User
6.3 Europe
6.3.1 Market Size &forecast (Value)
6.3.1 Market Size & forecast (Volume)
6.3.3 Western Europe
6.3.3.1 The U.K.
6.3.3.1.1 By Product
6.3.3.1.2 By End-User
6.3.3.2 Germany
6.3.3.2.1 By Product
6.3.3.2.2 By End-User
6.3.3.3 France
6.3.3.3.1 By Product
6.3.3.3.2 By End-User
6.3.2.4 Spain
6.3.2.4.1 By ProductBy Product
6.3.2.4.2 By End-User
6.3.2.5 Italy
6.3.2.5.1 By Product
6.3.2.5.2 By End-User
6.3.2.6 Rest of Western Europe
6.3.2.6.1 By Product
6.3.2.6.2 By End-User
6.3.4 Eastern Europe
6.3.4.1 By Product
6.3.4.2 By End-User
6.3.5 Rest of Europe
6.3.5.1 By Product
6.3.5.2 By End-User
6.4 Asia-Pacific
6.4.1 Market Size &forecast (Value)
6.4.2 Market Size & forecast (Volume)
6.4.3 Japan
6.4.3.1 By Product
6.4.3.2 By End-User
6.4.4 China
6.4.4.1 By Product
6.4.4.2 By End-User
6.4.5 Australia
6.4.5.1 By Product
6.4.5.2 By End-User
6.4.6 India
6.4.6.1 By Product
6.4.6.2 By End-User
6.4.7 South Korea
6.4.7.1 By Product
6.4.7.2 By End-User
6.4.8 Rest of Asia-Pacific
6.4.8.1 By Product
6.4.8.2 By End-User
6.5 The Middle East & Africa
6.5.1 The Middle East
6.5.1.1 Market Size &forecast (Value)
6.5.1.2 Market Size & forecast (Volume)
6.5.1.3 Saudi Arabia
6.5.1.2.1 By Product
6.5.1.2.2 By End-User
6.5.1.4 The UAE
6.5.1.4.1 By Product
6.5.1.4.2 By End-User
6.5.1.5 Qatar
6.5.1.5.1 By Product
6.5.1.5.2 By End-User
6.5.2 The Africa
6.5.2.1 Market Size &forecast (Value)
6.5.2.2 Market Size & forecast (Volume)
7 Company Profile
7.1 Abbott
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Recent Developments
7.1.4 Product Portfolio
7.2 Roche Diagnostics
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Recent Developments
7.2.4 Product Portfolio
7.3 Bayer AG
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Recent Developments
7.3.4 Product Portfolio
7.4 Medtronic Plc.
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Recent Developments
7.4.4 Product Portfolio
7.5 Novo Nordisk
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Recent Developments
7.5.4 Product Portfolio
7.6 Ypsomed AG
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Recent Developments
7.6.4 Product Portfolio
7.7 Senseonics, Incorporated
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Recent Developments
7.7.4 Product Portfolio
7.8 Dexom Inc
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Recent Developments
7.8.4 Product Portfolio
7.9 Insulet Corporation
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Recent Developments
7.9.4 Product Portfolio
8 Conclusion & Recommendations
9 Acronyms & Abbreviations
Table of Content and Figure @ https://straitsresearch.com/report/continuous-blood-glucose-monitoring-market/toc
News Media
Glucose Monitoring Devices Market: Effectiveness of Continuous Glucose Monitoring Devices
Have a Look at the Related Research Report
Continuous Glucose Monitoring Systems Market: Information by Component (Sensors, Transmitter, Receiver), End-Use (Hospitals, Home Healthcare), and Region — Forecast till 2030
Digital Diabetes Management Market: Introduction by Product (Smart Glucose Meter, CBGM), App (Digital Diabetes Management Apps), and Region — Forecast till 2030
Blood Testing Market: Information by Test Type (Glucose Testing, Liquid Panel Testing), End-User and Regional Outlook — Forecast Till 2026
Blood Glucose Lancets Market: Information by Type (Push Button Lancets, Side Activated Lancets), End-User (Hospitals and Clinics, Diagnostics Center), and Region — Forecast till 2029
Blood Pressure Monitoring Devices Market: Information by Product (Blood Pressure Transducers and Instrument & Accessories), End-Use (Hospitals & Homecare), and Region — Forecast till 2030
About Straits Research Pvt. Ltd.
StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)
+44 208 068 9665 (the U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter
